Source link : https://www.newshealth.biz/health-news/which-is-best-for-behcet-syndrome/
TOPLINE: Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time; both drugs also improve quality of life and disease activity scores. METHODOLOGY: Researchers conducted a phase 3 prospective study to evaluate the efficacy and safety of the anti–tumor necrosis […]
Author : News Health
Publish date : 2024-11-07 12:41:25
Copyright for syndicated content belongs to the linked Source.